RxDoctor Payments Data

Vivian Chang

Family · Margate, FLNPI 1942786546

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 28 payments — averaging $36.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$351
  • Lilly USA, LLC$152
  • Medtronic$144
  • AstraZeneca$111
  • Johnson & Johnson$95
  • Janssen Scientific Affairs, LLC$38
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$1,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,008 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$10,909
Medicare patients
80
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$48,547
EliquisApixaban26$25,334
FarxigaDapagliflozin Propanediol21$19,196
LinzessLinaclotide18$12,484
JanuviaSitagliptin Phosphate13$9,403
SymbicortBudesonide/Formoterol Fumarate14$5,030
Diclofenac Sodium111$1,906
SynthroidLevothyroxine Sodium13$1,671
Atorvastatin Calcium208$1,569
Losartan Potassium144$1,213
Memantine Hcl38$941
Rosuvastatin Calcium87$757
Fluticasone Propionate83$715
Famotidine55$672
Gabapentin101$665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$351$48,54749 claims
PfizerEliquis$18$25,33426 claims
AstraZenecaFarxiga, Symbicort$111$24,22635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Margate

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →